Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCU410ST for Stargardt Disease
NCT05956626Phase 3Active, not recruiting
- Sponsor
- Ocugen
- Start
- Aug 2023
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of OCU410ST in Stargardt disease (STGD) (2 arms), sponsored by Ocugen. Primary endpoints: Change from baseline in atrophic lesion size as measured by Fundus Auto Fluorescence at 12 months and Participants With Ocular and Non-ocular AEs and SAEs at 12 months. Started Aug 2023; status: active, not recruiting.
02
Drugs
OCU410ST
03
Conditions
Stargardt disease (STGD)
Beyond the preview
Go deeper on NCT05956626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05956626.